Published in Int J Breast Cancer on October 25, 2011
Phase II ABT-888 With Cyclophosphamide | NCT01306032
ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer | NCT01009788
An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer | NCT01130259
Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer. Onco Targets Ther (2013) 0.91
Minor grove binding ligands disrupt PARP-1 activation pathways. Oncotarget (2014) 0.84
PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1. J Cell Mol Med (2013) 0.79
Basal-like and triple-negative breast cancers: searching for positives among many negatives. Surg Oncol Clin N Am (2014) 0.79
Involvement of p53 in insulin-like growth factor binding protein-3 regulation in the breast cancer cell response to DNA damage. Oncotarget (2015) 0.79
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A (2003) 34.68
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature (2005) 26.32
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med (2009) 24.75
Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res (2004) 16.51
Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A (2003) 13.00
The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res (2007) 11.56
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol (2008) 11.03
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 9.72
Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res (2005) 9.70
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst (2003) 8.48
Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell (1997) 8.28
Epidemiology of basal-like breast cancer. Breast Cancer Res Treat (2007) 7.08
PARP inhibition: PARP1 and beyond. Nat Rev Cancer (2010) 6.70
Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst (2000) 6.38
Regulation of DNA double-strand break repair pathway choice. Cell Res (2008) 6.19
Resistance to therapy caused by intragenic deletion in BRCA2. Nature (2008) 5.85
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res (2007) 5.75
Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res (2005) 5.70
Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N Engl J Med (2011) 4.94
BRCA1 regulates human mammary stem/progenitor cell fate. Proc Natl Acad Sci U S A (2008) 4.79
BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene (2006) 3.91
Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. Mol Cell (1998) 3.86
Breast and ovarian cancer. N Engl J Med (2003) 3.84
The impact of a negligent G2/M checkpoint on genomic instability and cancer induction. Nat Rev Cancer (2007) 3.54
RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem (1997) 3.26
How basal are triple-negative breast cancers? Int J Cancer (2008) 3.18
Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Mol Cell Biol (2005) 3.10
Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res (2009) 2.59
Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol (2011) 2.56
Targeted therapy for cancer using PARP inhibitors. Curr Opin Pharmacol (2008) 2.40
Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol (2011) 2.33
The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J Pathol (2010) 2.23
Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer. Ann Oncol (2009) 1.97
Synthetic lethality--a new direction in cancer-drug development. N Engl J Med (2009) 1.84
Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. Cancer Biol Ther (2009) 1.60
PARP inhibitors stumble in breast cancer. Nat Biotechnol (2011) 1.47
Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis (2000) 1.46
Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors. Cancer Res (2010) 1.22
Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers. Am J Surg Pathol (2009) 1.17
Advanced stages and poorly differentiated grade are associated with an increased risk of HER2/neu positive breast carcinoma only in White women: findings from a prospective cohort study of African-American and White-American women. Breast Cancer Res Treat (2007) 1.07
PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. Breast Cancer Res Treat (2011) 0.99
Immunophenotypic predictive profiling of BRCA1-associated breast cancer. Virchows Arch (2010) 0.86
Understanding DNA damage response and DNA repair pathways: applications to more targeted cancer therapeutics. Semin Oncol (2009) 0.79
Overexpression of CXCR4 in primary tumor of patients with HER-2 negative breast cancer was predictive of a poor disease-free survival: a validation study. Ann Surg Oncol (2009) 1.42
Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence. J Surg Res (2007) 1.11
The chemokine receptor CXCR4 as a novel independent prognostic marker for node-positive breast cancer patients. J Surg Oncol (2012) 0.92
Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer? Surgery (2010) 0.91
Chemokine receptor CXCR4 level in primary tumors independently predicts outcome for patients with locally advanced breast cancer. Surgery (2011) 0.91
Elevated chemokine receptor CXCR4 expression in primary tumors following neoadjuvant chemotherapy predicts poor outcomes for patients with locally advanced breast cancer (LABC). Breast Cancer Res Treat (2008) 0.91
Does obesity have an effect on outcomes in triple-negative breast cancer? J Surg Res (2013) 0.89
Surgical versus nonsurgical management of traumatic major pancreatic duct transection: institutional experience and review of the literature. Pancreas (2013) 0.89
Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome. Surgery (2009) 0.89
CXCR4 and axillary lymph nodes: review of a potential biomarker for breast cancer metastasis. Int J Breast Cancer (2011) 0.85
The utility of a tissue slice model system to determine breast cancer infectivity by oncolytic adenoviruses. J Surg Res (2010) 0.84
CXCR4 as a predictive marker for locally advanced breast cancer post-neoadjuvant therapy. J Surg Res (2010) 0.81
Up-regulation of TLK1B by eIF4E overexpression predicts cancer recurrence in irradiated patients with breast cancer. Surgery (2006) 0.81
The role of chemokine receptor CXCR4 in the biologic behavior of human soft tissue sarcoma. Sarcoma (2010) 0.79
Sentinel lymph node biopsy in staging of differentiated thyroid cancer: a critical review. Surg Oncol (2002) 0.79
Is chronic kidney disease an independent risk factor for mortality in breast cancer? J Surg Res (2013) 0.78
Correlation of TLK1B in elevation and recurrence in doxorubicin-treated breast cancer patients with high eIF4E overexpression. J Am Coll Surg (2007) 0.78
The role of whole-body fluorine-18-FDG positron emission tomography in the detection of recurrence in symptomatic patients with stages II and III breast cancer. World J Surg (2006) 0.78
A novel suicide gene therapy targeting the overexpression of eukaryotic initiation factor 4E improves survival in a rat peritoneal carcinomatosis model. Surgery (2007) 0.76
Findings that hospital factors are surrogate for disparities are misleading. J Clin Oncol (2009) 0.75
Pediatric appendectomy: an example of a tailored approach to resident supervision. J Surg Res (2012) 0.75
Effect of January vacations and prior night call status on resident ABSITE performance. J Surg Educ (2013) 0.75
Resident Duty Hours and American Board of Surgery In-Training Examination Performance. Am Surg (2017) 0.75
Pediatric Pedestrians and Bicyclists versus Motor Vehicle Accidents: Comparison of Injury Patterns by Mechanism and Influence of Socioeconomic Status. Am Surg (2017) 0.75
Trimodal therapy for inflammatory breast cancer: a surgeon's perspective. Oncology (2010) 0.75
Surgical resident learning styles: faculty and resident accuracy at identification of preferences and impact on ABSITE scores. J Surg Res (2013) 0.75
Does the Insurance Status Predict the Outcome of the Trauma Patients with Abdominal Gunshot Wounds? Report from a Level I Trauma Academic Center with a Public Hospital. Am Surg (2016) 0.75
Two decades of humanitarian surgical outreach and capacity building in Kurdistan. Bull Am Coll Surg (2017) 0.75